<DOC>
	<DOCNO>NCT01372202</DOCNO>
	<brief_summary>This Phase 2 Study Paclitaxel Cisplatin versus Fluoropyrimidine Platinum Agent Neoadjuvant Therapy Operable Esophageal Cancer Based CHFR Methylation Status Diagnostic Biopsies .</brief_summary>
	<brief_title>CHFR Methylation Status Esophageal Cancer Study</brief_title>
	<detailed_description>Primary Objectives • To determine rate pathological complete response inclusion paclitaxel neoadjuvant therapy base presence absence CHFR methylation diagnostic biopsy specimen . Secondary Objectives - To determine survival outcome treatment strategy . - To determine time disease progression treatment strategy . - To determine agreement tumor CHFR methylation detection plasma .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma esophagus GE junction 2 . Patient must untreated chemotherapy , radiation therapy , surgery diagnosis esophageal cancer . ( Endoscopy biopsy dilation permit . ) 3 . Tumor must locate 20 cm teeth endoscopically 2 cm gastric cardia . Cervical esophageal cancer true gastric cancer exclude . 4 . Stage T23/N03/M0 determine image study biopsy appropriate . T4 disease permit defined resectable thoracic surgeon ( involvement pleura , pericardium diaphragm ) . 5 . Patients must endoscopic ultrasound 6 . Patients must stag PET scan 7 . Age ≥ 18 ≤ 75 8 . ECOG performance status 01 . 9 . Surgically resectable tumor 10 . Patients history curatively treated malignancy must diseasefree survival prognosis exceeds three year . 11 . Patients must adequate organ marrow function define : absolute neutrophil count ≥ 1,000/mcL platelet ≥ 100,000/mcL total bilirubin ≤ 2 mg/dL AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 X institutional ULN creatinine &lt; 1.5 X institutional ULN 12 . Female patient must pregnant breast feeding . Radiotherapy associate significant birth defect and/or nonviable fetus . Paclitaxel , cisplatin , oxaliplatin , 5fluorouracil teratogenic potential . A negative pregnancy test require within 14 day treatment woman childbearing potential . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant partner participate study , patient inform treat physician immediately . 13 . Patients must ability understand willingness sign write informed consent document . 1 . Patients may receive investigational agent . 2 . Incomplete heal previous major surgery . 3 . History allergic reaction attribute compound similar chemical biologic composition agent assign . 4 . Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital , St John 's Wort ; drug induce CYP3A may decrease level paclitaxel . 5FU strong CYP2C9 inducer , concomitant use carvedilol , celecoxib , fosphenytoin , fluoxetine , phenytoin , warfarin CYP2C9 substrates use caution . 5 . Uncontrolled , intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 6 . HIVpositive patient combination antiretroviral therapy ineligible patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate . 7 . Patients biopsy tissue obtain correlate study analysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Operable</keyword>
	<keyword>Based CHFR Methylation Status</keyword>
	<keyword>Diagnostic Biopsies</keyword>
</DOC>